Eulerpool/
Stock/
Altimmune/
Forward P/E

Altimmune Forward P/E

ALT

The Forward P/E Ratio of Altimmune (ALT) as of Jul 23, 2026 is -5.77. In the previous year, Forward P/E Ratio was -6.20 — a change of -6.96% (higher).

Get this data via API

Financial Data API

Forward P/E

-5.77

YoY

-6.96%

Last updated: Jul 23, 2026

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE

Forward P/E Ratio of Altimmune is 2026 -5.77 . Forward P/E Ratio of Altimmune was 2025 -6.20 . It decreases by -6.96% higher compared to the previous year.

Altimmune P/E Altimmune PEG Altimmune Earnings Growth Altimmune EPS

Access this data via the Eulerpool API

Docs Get Free API Key

Altimmune Stock analysis

What does Altimmune do? Altimmune Inc is a biopharmaceutical company specializing in the development of immunotherapies. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland, USA. Altimmune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Altimmune stock

Forward P/E Ratio of Altimmune is -5.77 in 2026.

Forward P/E Ratio of Altimmune changed from -6.20 to -5.77, representing a -6.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Altimmune since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Altimmune with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Docs Get Free API Key